Boston Scientific Announces Results For Third Quarter 2018

Go back to Boston Scientific Announces Results For Third Quarter 2018

Boston Scientific (BSX) Top Rating Maintained at Needham & Company Despite Mixed Qtr

October 24, 2018 12:52 PM EDT

Needham & Company analyst Mike Matson reiterated a Strong Buy and $43 price target on Boston Scientific (NYSE: BSX) as revenue missed consensus due to currency while its EPS beat consensus. Meanwhile, management lowered its revenue guidance due to currency and narrowed its EPS guidance.

Matson... More

Boston Scientific (BSX) Tops Q3 EPS by 1c, Updates Guidance

October 24, 2018 6:33 AM EDT

Boston Scientific (NYSE: BSX) reported Q3 EPS of $0.35, $0.01 better than the analyst estimate of $0.34. Revenue for the quarter came in at $2.39 billion versus the consensus estimate of $2.4 billion.

GUIDANCE:

Boston Scientific sees FY2018 EPS of $1.38-$1.40, versus the consensus of $1.40.... More